HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Douglas D Fang Selected Research

olverembatinib

1/2022FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.
1/2019Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Douglas D Fang Research Topics

Disease

12Neoplasms (Cancer)
07/2022 - 06/2012
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 12/2013
1Leukemia
01/2022
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/2019
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2019
1Liver Neoplasms (Liver Cancer)
12/2017
1Hepatocellular Carcinoma (Hepatoma)
08/2015
1Lung Neoplasms (Lung Cancer)
03/2014
1Carcinogenesis
03/2014
1Breast Neoplasms (Breast Cancer)
03/2013
1Tics (Tic)
03/2013
1Triple Negative Breast Neoplasms
03/2013
1Colorectal Neoplasms (Colorectal Cancer)
01/2013

Drug/Important Bio-Agent (IBA)

3Pharmaceutical PreparationsIBA
02/2016 - 06/2012
2Tyrosine Kinase InhibitorsIBA
07/2022 - 01/2022
2osimertinibIBA
07/2022 - 01/2022
2olverembatinibIBA
01/2022 - 01/2019
1Tetrazolium SaltsIBA
07/2022
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
07/2022
1Paclitaxel (Taxol)FDA LinkGeneric
07/2022
1Carboplatin (JM8)FDA LinkGeneric
07/2022
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
07/2022
1Aldehyde DehydrogenaseIBA
07/2022
1Drug CombinationsIBA
07/2022
1ErbB Receptors (EGF Receptor)IBA
07/2022
1MitogensIBA
07/2022
1trametinibIBA
07/2022
1STAT5 Transcription FactorIBA
01/2022
1LisaftoclaxIBA
01/2022
1pembrolizumabIBA
11/2019
1Immune Checkpoint InhibitorsIBA
11/2019
1Phosphotransferases (Kinase)IBA
01/2019
1Imatinib Mesylate (Gleevec)FDA Link
01/2019
1ponatinibIBA
01/2019
1Small Interfering RNA (siRNA)IBA
12/2017
1Doxycycline (Periostat)FDA LinkGeneric
12/2017
1CateninsIBA
12/2017
1ruxolitinibIBA
02/2016
1Messenger RNA (mRNA)IBA
03/2014
1CrizotinibIBA
03/2014
1Anaplastic Lymphoma KinaseIBA
03/2014
1Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
03/2014
1RNA (Ribonucleic Acid)IBA
03/2014
1GemcitabineFDA Link
12/2013
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
03/2013
1nirogacestatIBA
03/2013
1Docetaxel (Taxotere)FDA Link
03/2013
1SurvivinIBA
03/2013
12- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA
01/2013
1Biomarkers (Surrogate Marker)IBA
01/2013

Therapy/Procedure

6Therapeutics
07/2022 - 03/2013